Bain Capital Public Equity Management LLC raised its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 2,661.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 82,856 shares of the biopharmaceutical company’s stock after acquiring an additional 79,856 shares during the quarter. Bain Capital Public Equity Management LLC’s holdings in Nektar Therapeutics were worth $4,948,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of NKTR. Meeder Asset Management Inc. acquired a new stake in shares of Nektar Therapeutics in the fourth quarter valued at about $121,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of Nektar Therapeutics in the third quarter valued at about $129,000. Mark Sheptoff Financial Planning LLC grew its position in shares of Nektar Therapeutics by 79.4% in the third quarter. Mark Sheptoff Financial Planning LLC now owns 6,100 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 2,700 shares during the last quarter. SeaCrest Wealth Management LLC acquired a new stake in shares of Nektar Therapeutics in the fourth quarter valued at about $200,000. Finally, Kovack Advisors Inc. acquired a new stake in shares of Nektar Therapeutics in the fourth quarter valued at about $240,000. Institutional investors own 94.96% of the company’s stock.
Shares of Nektar Therapeutics (NKTR) opened at $108.34 on Monday. Nektar Therapeutics has a 1 year low of $14.96 and a 1 year high of $109.32. The firm has a market capitalization of $17,430.00, a PE ratio of -169.28 and a beta of 1.96. The company has a debt-to-equity ratio of 2.79, a quick ratio of 5.63 and a current ratio of 5.82.
NKTR has been the topic of several research analyst reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $80.00 price target (up from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th. Mizuho raised their price target on Nektar Therapeutics from $30.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, November 14th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $44.00 price target on shares of Nektar Therapeutics in a research report on Monday, November 13th. Jefferies Group raised their price target on Nektar Therapeutics from $2.12 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. Finally, Cowen reaffirmed a “buy” rating and issued a $101.00 price target on shares of Nektar Therapeutics in a research report on Friday, March 2nd. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $52.62.
In related news, SVP Stephen K. Doberstein sold 2,426 shares of Nektar Therapeutics stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $82.94, for a total transaction of $201,212.44. Following the sale, the senior vice president now directly owns 67,394 shares of the company’s stock, valued at $5,589,658.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Christopher A. Kuebler sold 40,000 shares of Nektar Therapeutics stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $97.60, for a total value of $3,904,000.00. Following the sale, the director now directly owns 43,100 shares in the company, valued at $4,206,560. The disclosure for this sale can be found here. Over the last three months, insiders have sold 482,925 shares of company stock worth $40,642,596. 6.10% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3256734/bain-capital-public-equity-management-llc-buys-79856-shares-of-nektar-therapeutics-nktr.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.